RxDoctor Payments Data

Shelly Quintanilla, NP

Family · Corpus Christi, TXNPI 1942963525

Payments from drug & device makers

$1,189in general payments, 2019–2025

Across 12 payments — averaging $99.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$143
  • Mylan Specialty L.p.$125
  • AbbVie$124
  • Idorsia Pharmaceuticals US Inc$124
  • Viatris Specialty LLC$122
  • Medtronic$117
  • plus $434 from 6 others

What the payments were for

  • Food & beverage$1,189100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,189 in reported general payments places this provider in the 70th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$6,808
Medicare patients
34
Services billed
139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$76,050
FarxigaDapagliflozin Propanediol61$55,785
JardianceEmpagliflozin43$47,576
JanuviaSitagliptin Phosphate29$31,803
RybelsusSemaglutide18$23,561
EliquisApixaban25$16,052
LinzessLinaclotide18$12,185
Xigduo XrDapaglifloz Propaned/Metformin22$12,105
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$8,968
SymbicortBudesonide/Formoterol Fumarate28$6,579
Omeprazole76$2,142
Albuterol Sulfate HfaAlbuterol Sulfate93$1,815
Gabapentin87$1,496
Atorvastatin Calcium186$1,442
Famotidine63$1,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$124$12,18518 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 15,456 family providers in Texas.

Other family in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →